Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.22M P/E - EPS this Y - Ern Qtrly Grth -
Income -6.94M Forward P/E - EPS next Y 66.70% 50D Avg Chg -1.00%
Sales 4.9M PEG - EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 0.53 EPS next 5Y - 52W High Chg -39.00%
Recommedations 2.00 Quick Ratio 4.83 Shares Outstanding 5.70M 52W Low Chg 42.00%
Insider Own - ROA -17.37% Shares Float 188.57M Beta 1.10
Inst Own 0.20% ROE -42.92% Shares Shorted/Prior 5.97K/3.45K Price 1.97
Gross Margin 68.06% Profit Margin -141.49% Avg. Volume 367,162 Target Price 5.01
Oper. Margin -131.96% Earnings Date Aug 29 Volume 3,940 Change 3.14%
About Immuron Limited

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Immuron Limited News
06:33 PM Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
11/18/24 Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
10/29/24 Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
10/16/24 Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
10/15/24 Immuron Travelan® continued strong sales growth
10/04/24 NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
10/03/24 Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)
09/24/24 Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
09/05/24 Immuron Plans Phase 2 Trial for IMM-529 following FDA review
06:00 AM Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
08/19/24 US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan
08/16/24 Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
08/15/24 Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
08/07/24 Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
07/17/24 Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
07/15/24 Immuron announces record Travelan® sales globally, Australia and USA
07/02/24 Immuron requests pre-IND meeting for IMM-529 with FDA filing
06/12/24 Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
05/31/24 Immuron CEO Steven Lydeamore to present at Peak Sky High
05/31/24 Immuron Board Changes
IMRN Chatroom

User Image Camila888 Posted - 3 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $AYTU $IMRN

User Image KoleSalinas Posted - 1 week ago

💥 Huge news expected for MYNZ soon 💥 Nov 12: 51M volume, +28%, with 19M short volume. With everyone awaiting the meeting results, I have a strong feeling the r/s extension will be pushed out another 180 days. Mainz Biomed (MYNZ) has partnered with Thermo Fisher (TMO, $209.2B market cap, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B revenue and advanced tech will boost MYNZ’s mRNA-based assays, achieving 85% detection for advanced adenomas, compared to competitors' 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Sentiment: Positive 1.⁠ ⁠Strategic partnership with industry giant Thermo Fisher 2.⁠ ⁠Access to Thermo Fisher's advanced tech 3.⁠ ⁠Potential for global commercialization 4.⁠ ⁠Development of home collection screening capability Win-win as TMO steps into the CRC market, too. Calling all apes, let’s crush the short sellers—this bull run is ours. $AYTU $IMRN

User Image topstockalerts Posted - 10/29/24

Pre Market Top Gainers PT2 $AREB $IMRN $NBY $VFC $DJT

User Image PharmaExpert Posted - 10/22/24

$AKBA, $PHUN, $IMRN, $INDP, $CYCC 🔥🔥🔥🔥🔥

User Image PenkeTrading Posted - 1 month ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Immuron Ltd ADR. Is that bullish or bearish? $IMRN #Immuron #RsiOversold #NASDAQ

User Image LewisDaKat Posted - 1 month ago

$IMRN News Article Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference https://marketwirenews.com/news-releases/immuron-ceo-steven-lydeamore-participation-in-maxim--8681244350341717.html $IMRN

User Image themacromindset Posted - 1 month ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference $IMRN

User Image briefingcom Posted - 1 month ago

Gapping up: $WOLF +29.3% $ERIC +10.2% $IMRN +6.2% $WBA +5.2%

User Image DonCorleone77 Posted - 1 month ago

$IMRN Immuron reports Q3 sales of Travelan up 13% vs. Q2 Immuron Limited announced continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Flavio Palumbo, Chief Commercial Officer, said, "As anticipated, we are achieving strong growth in North America with continued growth in Australia. We have secured core ranging in another nine pharmacy banner groups in Australia. We had our strongest monthly sales on Amazon in the US. We now have distribution in ten pharmacy/grocery retailers in Canada." Global sales of Travelan for the September 2024 quarter were AUD$1.5M, up 13% on prior quarter; for Australia, Travelan sales increased 3% to AUD$1.007M during the September 2024 quarter vs. AUD$0.983M for the June 2024 quarter. In North America, Travelan sales increased 48% to AUD$0.456M in the September 2024 quarter vs. AUD$0.309M in the June 2024 quarter.

User Image G101SPM Posted - 1 month ago

$IMRN $2.21 last. DAC (dollar average cost) (2) $2.32 (5.30.23). EXIT $6.50 (long term). UPDATE: Immuron announces Travelan has continued strong sales growth. ^^ Global September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia. ^^ September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America. ^^ September 2024 Quarter AUD$0.5 million up 48% on prior quarter.

User Image themacromindset Posted - 1 month ago

$IMRN Immuron Travelan® continued strong sales growth

User Image topstockalerts Posted - 1 month ago

Pre Market Top Gainers PT2 $INAB $JSPR $IMRN $WHLR $GMM

User Image topstockalerts Posted - 1 month ago

Pre Market Top Gainers PT2 $PW $AMLI $BLMZ $AKAN $IMRN

User Image Red2Profit Posted - 1 month ago

$IMRN News! Halt up

User Image sevendrax77 Posted - 1 month ago

$IMRN what happened? News?

User Image risingstarsbynature Posted - 09/26/24

$IMRN buy Rating https://fox40.com/business/press-releases/ein-presswire/745762816/mecca-capital-fund-mecca-capital-partners-initiates-a-buy-rating-on-immuron-limited-nasdaq-imrn/

User Image jParkz Posted - 09/24/24

$IMRN News Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now https://marketwirenews.com/news-releases/presenting-on-the-emerging-growth-conference-75-day--7893685854203893.html $IMRN

User Image ButterCapital Posted - 09/23/24

$IMRN buy order hit

User Image Doozio Posted - 2 months ago

$IMRN FRYdays during 🧠⏰♾️

User Image G101SPM Posted - 2 months ago

$IMRN $2.74 bid. DAC (2) $2.32 (5.30.23). EXIT $6.50 long term. UPDATE: Announced it has received favorable feedback from FDA on the pre-IND (investigational new drug) information package to support the clinical development of IMM-529.

User Image Stock_Titan Posted - 2 months ago

$IMRN Immuron Plans Phase 2 Trial for IMM-529 following FDA review https://www.stocktitan.net/news/IMRN/immuron-plans-phase-2-trial-for-imm-529-following-fda-ztuuapvn4j0c.html

User Image Doozio Posted - 08/30/24

$IMRN chop chop huckleberries thiiiiiin to win in 🧠⏰

User Image PharmaExpert Posted - 3 months ago

$AKBA, $STXS, $BMRA, $IMRN, $AGRX 🔥🔥🔥🔥🔥

User Image Stock_Titan Posted - 3 months ago

$IMRN Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® https://www.stocktitan.net/news/IMRN/immuron-announces-new-u-s-department-of-defense-research-award-for-uhvmurmhlhik.html

User Image G101SPM Posted - 3 months ago

$IMRN $2.27 last. DAC (2) $2.32. EXIT $6.50 (long term) UPDATE: Hosting webinar on Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). note: Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps.

User Image G101SPM Posted - 4 months ago

#SPMNOTES Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now * $IMRN $ 2.68 * $CVKD $0.450499 * Hold long positions The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

User Image Kevin_Gough Posted - 4 months ago

$IMRN Great news!!!

User Image Kevin_Gough Posted - 4 months ago

$IMRN Great news!!!

User Image DonCorleone77 Posted - 4 months ago

$IMRN Immuron announces record Travelen sales globally Immuron announced record sales of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Australia: Sales of Travelan increased 236% to AUD $3.7 million for the full financial year to June 2024 compared to AUD $1.1 million for FY23. Sales of Travelan increased 209% to AUD $1.0 million for the June 2024 Quarter compared to AUD $0.3 million for the June 2023 Quarter. Consistent with the increase in June 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in April 2024 were 29% higher than April 2023. USa: We achieved a new annual record. The previous highest annual USA sales was AUD $1.0 million in FY19. Sales of Travelan increased 74% to AUD $1.1 million for the full financial year to June 2024 compared to AUD $0.6 million for FY23. Sales of Travelan increased 546% to AUD $0.3 million in the June 2024 Quarter compared to AUD $0.05 million in the June 2023 Quarter. Immuron's experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in April 2024 being 8% higher than in April 2023.

User Image Stock_Titan Posted - 4 months ago

$IMRN Immuron announces record Travelan® sales globally, Australia and USA https://www.stocktitan.net/news/IMRN/immuron-announces-record-travelan-r-sales-globally-australia-and-1pvntym9vthz.html

Analyst Ratings
Litchfield Hills Buy Sep 26, 24
HC Wainwright & Co. Buy Oct 18, 17